tbuckley/cabot-search huggingface dataset:
Phase 1 clinical trial of KOS-953 + bortezomib (BZ) in relapsed refractory multiple myeloma (MM)
Authors: A. Chanan-Khan, P. Richardson, M. Alsina, S. Lonial, A. Krishnan, M. Carroll, M. Albitar, A. L. Hannah, R. G. Johnson, K. Anderson
Journal: Journal of Clinical Oncology (2006)

3066 Background: KOS-953 (17-AAG in Cremophor) inhibits HSP90 chaperone function, resulting in disruption of protein complexes and proteasomal degradation. Single-agent 17-AAG is active in relapsed/refractory MM patients (pts) (ASH 2005 A#361), with a recommended dose ≥ 275 mg/m 2 . In vitro, BZ + KOS-953 show additive cytotoxicity of myeloma cells. Objectives: Define phase 2 dose of BZ+KOS-953 in pts with relapsed refractory MM. Determine PK of KOS-953 and its active metabolite. Evaluate proteasome inhibition in whole blood lysates and explore changes in intracellular signaling proteins in pt PBMCs and MM cells. Methods: Pts received BZ as IV bolus followed by 1-hour infusion KOS-953 twice weekly for 2 out of 3 weeks. Dose escalation occurred in a step-wise manner. PK and collection of surrogates are performed following the 1 st and 4 th infusion. Pts assessed for response by EBMT criteria. Results: 20 pts were enrolled in 4 cohorts: BZ+KOS-953 (mg/m 2 ): 0.7+100 (n=3); 1.0+100 (n=3); 1.0+150 (n=8); and 1.3+150 (n=6), receiving a total of 103+ cycles (median 5 cycles; range &lt;1 - 17). Demographics: 10F/10M; median age/KPS 64y/90; median # of prior regimens 4 (range 2–16); 75% prior BZ (5 with ≥2 prior BZ); 95% prior thalidomide; 15% prior lenalidomide; 70% prior SCT(s). DLT observed in Cohort 2 (n=1 grade 4 hepatotoxicity in a setting of congestive heart failure secondary to cardiac amyloidosis) and in Cohort 3 (n=1 pancreatitis). Other Grade 3–4 toxicity (1 each): thrombocytopenia with Herpes Zoster recurrence and pneumonia; septic thrombophlebitis. Drug-related toxicity (mild-to-moderate): diarrhea (n=8), fatigue (n=8), constipation (n=7), neuropathy (n=7), ↑AST (n=5), muscle cramps (n=5) and rash (n=4). PK similar to single-agent trial; stationary kinetics noted upon twice weekly dosing. 20S proteasome function (1.3 mg/m 2 , end of infusion): 50% decrease (similar to predicted values). Response was seen in 6 out of 12 BZ-refractory patients (1 nCR, 5 MR) and 3 out of 4 BZ-naïve pts (1 nCR, 2 MR). Conclusions: Dose escalation continues with no additive toxicity or PK interactions to date. Similar inhibition of the 20S proteasome is observed compared to BZ alone. Encouraging activity is seen in both BZ-naïve and BZ-refractory heavily pre-treated MM pts. [Table: see text]
Abstract 285: Granzymes: Major Players in Vascular Remodelling, Atherosclerosis and Longevity
Authors: Rani P Cruz, Wendy A Boivin, Ciara M Chamberlain, Jonathan C Choy, Bruce M McManus, David J Granville
Journal: Circulation (2007)

Introduction: Granzymes A and B (GrA/GrB) are cytotoxic proteases that are released by immune cells to eliminate target cells. GrB is present in human vessels and its expression corresponds to increased disease severity. In addition to their cytotoxic roles, in conditions of chronic inflammation, GrA and GrB may contribute to the degradation of extracellular matrix (ECM) proteins leading to tissue degeneration. Hypothesis: GrA and GrB levels are elevated in atherosclerotic patients and play a key role in the degradation of ECM and atherosclerosis. Methods: ApoE −/− x GrB −/− double knockout (apoE/GrB-DKO) mice were generated. C57-wt, GrB-KO, apoE-KO or apoE/GrB-DKO mice were fed a high fat diet for 30 weeks, sacrificed, tissues processed and lesion morphology and morphometry assessed. GrA and GrB levels were also measured in human plasma from patients with or without clinically evident atherosclerosis by ELISA. GrA/GrB-mediated ECM proteolytic activity was also assessed. Results: GrB deficiency significantly reduced the development of xanthomatosis, hair loss and atherosclerosis in the apoE-KO mice. GrB deficiency resulted in a marked reduction of elastin degradation in both the skin and blood vessels. GrB was found to co-localize to elastin fibres in atherosclerotic plaques and was capable of binding to, and cleaving elastin in vitro. ECM cleavage assays demonstrated that GrA and GrB cleave other ECM such as fibronectin. Preliminary studies indicate that GrB deficiency increases the lifespan of the apoE-KO mice as the apoE/GrB-DKO mice can survive up to 60 weeks of age on a high fat diet with no external indication of disease, skin degeneration or hair loss. In humans, preliminary evidence indicates that GrA/GrB levels are elevated in atherosclerosis. Smoking also appears to elevate plasma granzyme levels. Conclusions: During chronic inflammation, granzymes accumulate extracellularly and exhibit proteolytic activity towards extracellular matrix proteins that results in vascular remodeling and atherosclerosis with age. Attenuation of GrB resulted not only in a significant reduction of atherosclerosis, but also prolonged the lifespan of apoE-KO mice.
TCT-656 Outcome Of Implantation Of Second Self Expanding Valve For The Treatment Of Residual Moderate Or Severe Aortic Regurgitation In Transcatheter Aortic Valve Replacement Patients
Authors: Edward Koifman, Gaby Weissman, Romain Didier, Arpi Tavil-Shatelyan, Nirav S. Patel, Sandeep Kumar, Joelle S. Salmon, Sarkis Kiramijyan, Smita I. Negi, Itsik Ben Dor, Ricardo O. Escarcega, Marco A. Magalhaes, Rebecca Torguson, Petros Okubagzi, Lowell F. Satler, Augusto Pichard, Ron Waksman
Journal: Journal of the American College of Cardiology (2015)
Comparable Outcomes of High-Resolution HLA-Matched Unrelated and HLA-Identical Sibling Donor Stem Cell Transplantation for Childhood Acute Myeloid Leukemia in First Remission.
Authors: Dae-Hyoung Lee, Young-Joo Kwon, Nak-Gyun Chung, Dae-Chul Jeong, Hack-Ki Kim, Bin Cho
Journal: Blood (2007)
Prognostic role of body mass index (BMI) in patients with metastatic castration resistant prostate cancer (mCRPC) receiving chemotherapy: Preliminary results from a retrospective Italian multicenter study.
Authors: Stefania Eufemia Lutrino, Caterina Fontanella, Orazio Caffo, Francesco Massari, Francesco Atzori, Claudia Maggi, Nicola Calvani, Cosimo Sacco, Antonello Veccia, Alessandra Modena, Silvia Cugudda, Elena Verzoni, Chiara Caliolo, Paola Ermacora, Francesca Maines, Giampaolo Tortora, Giuseppe Procopio, Pasqualinda Ferrara, Gianpiero Fasola, Saverio Cinieri
Journal: Journal of Clinical Oncology (2016)

342 Background: Body mass index (BMI) is linked to an increased risk of cancers and a poorer prognosis. However, the evidence on the relationship between high BMI and metastatic castration resistant prostate cancer (mCRPC) is not entirely consistent and the data are conflicting. The aim of this observational, retrospective, multicenter study was to evaluate the correlation between BMI and progression-free survival (PFS) and overall survival (OS) in patients (pts) with mCRPC treated with chemotherapy. Methods: We collected mCRPC pts who received docetaxel 75 mg/m2 every 21 days as first line therapy in6 Italian Cancer Centers from 2005 to 2015. We classified BMI group according with the World Health Organization definition : normal weight BMI &lt; 25kg/m2, overweight 25 ≤ BMI &lt; 30kg/m2, and obese BMI ≥ 30kg/m2. Baseline characteristics and treatment information has been recorded in an anonymized excel file. Results: We collected 113 pts with a median age of 70.7 years (62 to 87) at the time of mCRPC diagnosis. In our cohort 33.6% of pts were normal weight at the HRPC diagnosis, 50.9% were overweight, and 15.5% were obese. At the baseline, 83.3% of obese pts had at least 1 co-morbidity versus 64.9% of normal/overweight pts. Moreover, 27.8% of obese pts needed a docetaxel dose reduction versus 17.5% normal/overweight pts. Only a non-significant trend for the detrimental effect of high BMI on PFS and OS has been documented. Median PFS in obese pts 6.4 months vs 7.0 months in of normal/overweight pts (p = 0.439); median OS in obese pts 38.8 months vs 43.4 months in of normal/overweight pts (p = 0.157). Conclusions: The relationship between BMI and mCRPC is extremely complex and unclear. Even if in this preliminary analysis we failed to confirm a significant association between BMI and survival, the data suggests that obesity may be associated with a lower tolerance to chemotherapy. Overall, we expected to enroll approximately 500 pts and data collection is currently ongoing.
TCT-537 Three-Year Comparison of Vessel Remodeling Between a Novel Non-Drug Eluting Bioresorbable Stent and Bare Metal Stent in Porcine Coronary Arteries
Authors: Lijie Wang, Gaoke Feng, Pawel Gasior, Yanping Cheng, Edward A. Estrada, Jenn McGregor, Kamal Razipoor, Gerard B. Conditt, Chang Lee, Torsten P. Vahl, Juan Granada, Greg L. Kaluza
Journal: Journal of the American College of Cardiology (2015)
The Histone Deacetylase Inhibitor Sodium Valproate Has In Vitro Anti-Neoplastic Activity Against Primary Multiple Myeloma Cells and Cell Lines Both Alone and in Combination with Velcade.
Authors: Supratik Basu, F. L. Khanim, R. E. Hayden, A. Barkhuinzen, A. MacWhannel, A. Jacob, S. Handa, C. Craddock, M. T. Drayson
Journal: Blood (2005)
An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma.
Authors: James M. G. Larkin, Paola Queirolo, Ana M Arance, Michael Paul Brown, Axel Hauschild, Michele Del Vecchio, Grant A. McArthur, Bart Neyns, Jürgen C. Becker, Johan Hansson, David Hogg, Paolo Antonio Ascierto, Carmen Loquai, Enrique Espinosa, Claus Garbe, Poulam M Patel, Jacob Schachter, Lada Mitchell, Maria Luisa Veronese, Christian U. Blank
Journal: Journal of Clinical Oncology (2012)

8517 Background: Vemurafenib, a BRAF inhibitor, is associated with improved PFS and OS in patients (pts) with BRAF V600 -mutant metastatic melanoma (mM). We present preliminary safety and efficacy findings from a safety study of vemurafenib in pts with unresectable stage IIIC/IV mM with BRAF V600 mutations. Methods: Pts with untreated or previously treated stage IIIC/IV BRAF V600 mutation-positive (cobas 4800 BRAF V600 Mutation Test) melanoma were enrolled. Pts received continuous oral vemurafenib 960 mg bid. Primary study endpoint was safety; efficacy (RECIST V 1.1) was a secondary endpoint. Results: Of 1,964 screened pts between Mar and Sep 2011, 914 (47%) were enrolled and 834 were evaluable for safety. Median age was 53 (21–88 years), 55% males. Median time since first mM diagnosis was 7.6 months (0–18 years). At baseline, 80% of pts had ECOG PS 0–1, 11% ECOG PS 2 (missing 9%); 27% of pts had brain metastases, and 31% had elevated LDH. Most pts had received prior systemic therapy (70%) including ipilimumab (14%), MEK and BRAF inhibitors (2%). At data cut-off (Sep 30, 2011), median treatment duration was 68 days (1–223 days) with 87% of pts still on treatment. Of 834 pts, 553 (66%) to date have reported AEs. Of 553 pts reporting AEs, 88% were related to vemurafenib, 33% Grade 3, and 1.9% Grade 4. The most common (&gt;1%) Grade 3/4 AEs were rash (3.6%), arthralgia (3.1%), and cutaneous squamous cell carcinoma/keratoacanthoma (4.3%). Most common AEs (&gt;10%) of any grade were arthralgia (31%), rash (29%), fatigue (22%), photosensitivity (21%), nausea (15%), and were similar irrespective of brain metastases and ECOG PS. AEs caused treatment interruption in 141 (17%) pts. Of 109 pts who discontinued treatment (13%), main reasons for withdrawal were progressive disease (60%), death (20%), AEs (6%; most commonly arthritis and abdominal pain). Tumor assessments at Week 8 of treatment were available for 302/834 (36%) pts, 61% pts achieved CR or PR, and 29% had SD. Conclusions: In a setting representative of routine clinical practice, vemurafenib is seen to be well tolerated and both safety profile and activity resemble the phase I–III data although this analysis is limited by the study duration.
GW27-e0398 Mitogen-activated protein kinase interacting kinase 1 (Mnk1) Deficiency Aggravates Cardiac Remodeling via Regulation of Sprouty2-dependent ERK1/2 pathway
Authors: Yuan Yuan, Ling Yan, Qing-Qing Wu, Heng Zhou, Ya-Ge Jin, Zhou-Yan Bian, Wei Deng, Zheng Yang, Di-Fei Shen, Xiao-Feng Zeng, Sha-Sha Wang, Hongliang Li, Qi-Zhu Tang
Journal: Journal of the American College of Cardiology (2016)
Use of CMV Unselected Blood Products Does Not Increase the Risk of CMV Reactivation in Patients Undergoing Hematopoetic Stem Cell Transplant (HSCT)
Authors: Jayne Peters, Jonathon Elliott, Adrian Bloor, Michael Dennis, John Murray, Jim Cavet, Tim Somervaille, Sven Armin Sommerfeld, Ken Mutton, Kaz Mamat, Malcolm Guiver, Samar Kulkarni
Journal: Blood (2015)
TCT-688 Acute, 30 and 90-day results of the STASIS trial: a multi-center study on a novel apical closure device for transapical transcatheter aortic valve implantation
Authors: Hendrik Treede, Lenard Conradi, Thomas Walther, Joerg Kempfert, Sabine Bleiziffer, Walter Eichinger, Oliver Heyn, Hermann Reichenspurner, Riccardo Cocchieri, Ruediger Lange
Journal: Journal of the American College of Cardiology (2015)
TCT-381 Worsening renal function is strongly associated with long-term mortality in stable post-myocardial infarction 1-year survivors
Authors: Young Soo Lee, Kwan Yong Lee, Sungmin Lim, Ha-Wook Park, Byung-Hee Hwang, Young Choi, Tae-Hoon Kim, Yoon Seok Koh, Hun Jun Park, Pum Joon Kim, Kiyuk Chang, Wook Sung Chung, Hee-Yeol Kim, Dong-Bin Kim, Jong Min Lee, Chul Soo Park, Ki Dong Yoo, Doo Soo Jeon, Sung-Ho Her, Youngkeun Ahn, Myungho Jeong, Ki-Bae Seung
Journal: Journal of the American College of Cardiology (2015)
Impact of Post-Remission Therapy on Survival of Older Patients with AML Treated with Intensive Chemotherapy: Results of the Multicenter ALFA-9803 Trial.
Authors: Pascal Turlure, Claude Gardin, Jean-Valere Malfuson, Xavier Thomas, Christine Terre, Nathalie Contentin, Emmanuel Raffoux, Stephane de Botton, Cecile Pautas, Oumedaly Reman, Jean-Henri Bourhis, Nathalie Dhedin, Maud Janvier, Pierre Fenaux, Sylvie Castaigne, Mauricette Michallet, Claude Preudhomme, Thierry de Revel, Dominique Bordessoule, Herve Dombret
Journal: Blood (2006)
Efficacy of Plerixafor Administered At 5:00PM for Stem Cell Mobilization in Lymphoma and Myeloma Patients Undergoing Autologous Stem Cell Transplant,
Authors: Jennifer Tornatta, John J. Maciejewski, Sunita Nathan, Bruce Mcleod, Sridevi Palaparthy, Elizabeth Shima Rich, Kent W Christopherson, Stephanie A. Gregory, Henry C. Fung
Journal: Blood (2011)
The BET Bromodomain Inhibitors EP11313 and EP11336 Have Potent Anti-Leukemic Activity in Acute Myeloid Leukemia (AML) and Augment the Effects of All-Trans-Retinoic Acid (AtRA) in Vitro
Authors: Ronan T. Swords, Shaun Brothers, Nagi Ayad, Aymee Perez, Justin M. Watts, Fernando Vargas, Roy Elias, Ana Rodriguez, Shawn Johnstone, Jeffrey Albert, Joseph Collard, Arthur Zelent, Claes Wahlestedt
Journal: Blood (2015)
GW27-e0346 The retrospective study of clinical characteristics and risk factors in patients that complicated with pneumonia after stroke
Authors: Xiaoyong Xiao, Zhenhua Huang, Zi Ye, Peng Jiang, Yan Xiong, Jia Xu, Jinli Liao, Zhengke Huang, Yingxiong Huang, Hong Zhan
Journal: Journal of the American College of Cardiology (2016)
TCT-34 Completeness of defect closure determined the resolution of hemolytic anemia in patients undergoing transcatheter paravalvular leak closure
Authors: Grzegorz A. Smolka, Piotr Pysz, Michał Kozłowski, Tomasz Roleder, Wojciech Zasada, Lukasz Partyka, Dariusz Dudek, Andrzej J. Ochala, Michal Tendera, Wojciech Wojakowski
Journal: Journal of the American College of Cardiology (2015)
The Splicing Factor Heterogeneous Nuclear Ribonucleoprotein L (hnRNPL) Restricts p53 Dependent and p53 Independent Cell Death Pathways In Hematopoietic Stem Cells
Authors: Marie-Claude Gaudreau, Damien Grapton, Florian Heyd, Charles Vadnais, Brian T Wilhelm, Tarik Moroy
Journal: Blood (2013)
SPECT/CT in Melanoma Lymphoscintigraphy
Authors: Khimling Tew, David Farlow
Journal: Clinical Nuclear Medicine (2016)

Sentinel lymph node biopsy is a crucial part of staging intermediate and thick melanoma. Lymphatic drainage from a tumor site can be highly variable, especially on the head, neck, and trunk. SPECT/CT fuses nuclear medicine and x-ray CT images to produce images with high anatomic detail. At our institution, SPECT/CT is performed routinely in addition to planar imaging. This article presents examples where SPECT/CT has proven helpful in image interpretation.
Challenging Problems in Advanced Malignancy
Authors: Lewis J. Kampel
Journal: Journal of Clinical Oncology (2003)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2003.08.102 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12915609 Challenging Problems in Advanced Malignancy CASE 2. DISSEMINATED INTRAVASCULAR COAGULATION IN METASTATIC HORMONE-REFRACTORY PROSTATE CANCER Lewis J. KampelxLewis J. KampelSearch for articles by this author Show More Memorial Sloan-Kettering Cancer Center, New York, NY https://doi.org/10.1200/JCO.2003.08.102 First Page Full Text PDF Figures and Tables © 2003 by American Society of Clinical Oncology
Pre-Emptive Granulocyte Transfusions (GTX) in Pediatric Patients with a Chronic Bacterial or Fungal Infection Undergoing a Hematopoietic Stem Cell Transplantation (HSCT).
Authors: Raphael F. Sharon, H. Vrielink, M. B. Bierings, A. B. Versluijs, J. J. Boelens
Journal: Blood (2005)
Comparison of various EGFR tyrosine kinase inhibitors (TKIs) for tumors with exon 18 mutations of the EGFR gene
Authors: Tetsuya Mitsudomi, Yoshihisa Kobayashi, Yosuke Togashi, Hiroshi Mizuuchi, Kenichi Suda, Kazuto NIshio
Journal: Annals of Oncology (2015)
STUDIES ON TUBERCULOSIS: CHAPTER III. THE DERIVATION OF GIANT CELLS WITH ESPECIAL REFERENCE TO THOSE OF TUBERCULOSIS
Authors: C. A. Doan
Journal: The Journal of Experimental Medicine (1930)

1. There are two types of giant cells discriminated by their method of formation; one is derived from a single monocyte or epithelioid cell and the other by the fusion of cells.

2. The epithelioid giant cell is formed by amitotic nuclear division; it tends to be small, simple, and relatively uniform in structure; its essential structure is a rosette of fine vacuoles which in the living state are stainable with neutral red.

3. The foreign body types show extreme variation in size and structure, according to the nature and the number of the cells out of which they are made. They lack any constant cytoplasmic pattern.

4. Both of these types of giant cells are probably formed in response to the need for phagocytosis of foreign material.

5. In tuberculosis it is probably only certain specific portions of the lipoids that induce the production of mono- and multinucleated epithelioid cells.

6. The stimuli for the formation of giant cells of the foreign body type are much more varied than those which produce epithelioid giant cells.
Activation of NFAT and NFkB Transcription Factors upon B Cell Receptor (BCR) Stimulation Is Restricted to Evolutive Chronic Lymphocytic Leukemia (CLL) Cases.
Authors: Nathalie S. Chevallier, Pierre-Antoine Deglesne, Taoufik Beitar, Fanny Baran-Marszak, Remi Letestu, Amalia Vlad, Valerie Lefebvre, Isabelle Clavereau, Florence Cymbalista, Nadine Varin-Blank
Journal: Blood (2006)
TCT-279 The value of image fusion in coronary angiography for the detection of coronary artery bypass grafts
Authors: Julien Plessis, Karine Warin Fresse, Zakary Cahouch, Vincent Letocart, Thibaut Manigold, Maxime Lamer, Laurianne Le Gloan, Patrice Guerin
Journal: Journal of the American College of Cardiology (2015)
TCT-733 Acute Hemodynamic Effects of Percutaneous Transluminal Caval Flow Intermittent Restriction with Balloon, in Ischemic and Non Ischemic Heart Failure Patients
Authors: Jose E. Herrera, Roberto Cubeddu, William Torres, Luis Velasco, Bartolomé Finizola, Gabriel D'Empaire, Jose A. Octavio, Eleazar Garcia, Jose A. Herrera, Robert Levine, Igor F. Palacios
Journal: Journal of the American College of Cardiology (2015)
Expression Profiling Of Selected Polycomb Complex Genes In Childhood Acute Myeloid Leukemia Revealed An Overexpression Of EZH2 In Acute Promyelocytic Leukemia
Authors: Amanda Faria Figueiredo, Renata Binato, Andre Mencalha, Roberto Capela Matos, Raul C Ribeiro, Maria Luiza Macedo Silva, Eliana Abdelhay
Journal: Blood (2013)
Estrogen receptor-beta expression and outcomes in breast cancer: A meta-analysis.
Authors: Jieqiong Liu, Huishan Guo, Fengxi Su, Qiang Liu
Journal: Journal of Clinical Oncology (2015)

e22056 Background: Estrogen receptor (ER)-β has been discovered for decades, however, its prognostic value in breast cancer patients remains controversial. We aimed to evaluate the effect of ER-β expression on breast cancer survival. Methods: A systematic search of Medline, Embase, and the Cochrane Library was performed to identify the association between ER-β expression and outcomes in early breast cancer patients. Random-effects meta-analysis was conducted to generate combined hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS) and disease-free survival (DFS). Results: A total of 3897 patients for ER-β1 and 1505 patients for ER-β2 from 15 studies were included. ER-β1 protein expression was correlated with both favorable DFS and OS at 5 years (HR: 0.593, 95% CI: 0.498-0.707, P < 0.001; HR: 0.551, 95% CI: 0.448-0.678, P < 0.001), while ER-β1 mRNA had no significant association with DFS (HR: 0.915, 95% CI: 0.581-1.440, P = 0.700). ER-β2 protein was associated with improved 5-year DFS (HR: 0.481, 95% CI: 0.338-0.683, P < 0. 001), but not OS (HR: 0.692, 95% CI = 0.326-1.466, P = 0.336). Subgroup analysis showed that higher ER-β1 expression was associated with better 5-year DFS in both ER-α positive and negative patients, but the positive association between ER-β1 expression and 5-year OS was only seen in ER-α positive patients. Conclusions: Wild-type ER-β (ER-β1) and its variant ER-β2 protein expressions are associated with better survival in early breast cancer patients. The prognostic significance of ER-β1 for DFS is independent of ER-α coexpression, whereas the impact on OS was only in ER-α positive breast cancer.
Removal of Macrophages From the Erythroid Niche Impairs Stress Erythropoiesis but Improves Pathophysiology of Polycythemia Vera and Beta-Thalassemia
Authors: Pedro Ramos, Carla Casu, Sara Gardenghi, Laura Breda, Bart J Crielaard, Ritama Gupta, Ella Guy, Maria F Mariongiu, Ross L. Levine, Omar Abdel-Wahab, Benjamin L. Ebert, Nico van Rooijen, Saghi Ghaffari, Robert W Grady, Patricia Giardina, Stefano Rivella
Journal: Blood (2012)
GW27-e0516 Gender features in the risk of arterial hypertension in general population with personal anxiety in Russia/Siberia WHO program MONICA-psychosocial epidemiological study
Authors: Valery Gafarov, Elena Gromova, Dmitriy Panov, Igor Gagulin, Almira Gafarova, Olga Esipenko
Journal: Journal of the American College of Cardiology (2016)